Report      Database

    Global Vaccines Market & Forecast (14 Vaccines Market, Number of People Immunized Doses of Vaccines Administered)

    Date: 16 Aug, 2017              Type: Vaccines              Pages: 318

    Global Vaccines Market & Forecast (14 Vaccines Market, Number of People Immunized  Doses of Vaccines Administered)
    • Electronic Access - Single User License
      $2,200.00
    • CD-ROM Mail Delivery
      $2,300.00
    • Hard-copy Mail Delivery
      $2,450.00
    • Electronic Access - Multi User License
      $3,000.00

    Get 10% Free Customization in this Report

    Global Vaccines Market to reach US$ 60 Billion by the year 2022. Pediatric vaccines market is having a dominant market share compared to Adult vaccines market. By 2022 Pediatric vaccines market share will be double the size of adult vaccines market share. Worldwide the number of infants immunized by influenza vaccines remain considerably low than that of adults immunized in year 2017. While the number of Rotavirus doses administered in infants is forecast to increase over the years and reach nearly 15 Million by the year 2022.       

     

    Adult Vaccine Market Share Analysis

    Out of the total 9 Adult vaccines (Influenza, Cervical Cancer, Zoster, MMRV, Pneumococcal, Meningococcal, Hepatitis, TdaP, Travel) studied in the report Influenza vaccines dominates the adult vaccine market in 2017.

     

    Pediatric Vaccine Market Share Analysis

    Our analysis found that in year 2017; Pneumococcal and Combination vaccine together accounts for nearly 50% of the pediatric vaccine market share. Other Pediatric vaccines market studied in the report are as follows: Influenza, MMR, Pneumococcal, Meningococcal, Hepatitis, DTap, Haemophilus Influenzae Type b(Hib), Combos, Polio, Rotavirus, Varicella.

     

    In 2017 Combos Vaccines will control the Immunization Share

    For the year 2017; Combos (Combination Vaccines) has the maximum immunization share among all pediatric vaccines (Influenza, MMR, Pneumococcal, Meningococcal, Hepatitis, DTap, Haemophilus Influenzae Type b(Hib), Polio, Rotavirus, Varicella) studied in the report as they protect against more ailments in single shot, people preferring to get combination vaccine instead of a specific vaccine.

     

    Administration of Vaccine Doses

    Our analysis found that there is a consistent surge in the number of Pneumococcal and Meningococcal vaccine doses administration in future due to the rising concern against the life-threatening vaccine-preventable diseases around the world.

     

    Global Vaccines Market & Forecast (14 Vaccines Market, Number of People Immunized  Doses of Vaccines Administered) is the 8th edition of market research report published by Renub Research on Global Vaccines Market. This is a 318 page report with 193 Figures and 44 Tables provides data of Global Vaccine Market (Adult & Pediatrics), People Immunized, Number of Vaccine Doses Administered (Disease wise) & Key Players. Vaccine has been extensively studied from 3 major points, and further sub-divided into 2 more points:    

    1.    World Vaccines (Disease wise) Market & Forecast (2011 – 2022)

    a.    Adult Vaccines Market & Forecast
    b.    Pediatrics Vaccines Market & Forecast

    2.    People Immunized (Disease wise) & Forecast (2011 – 2022)

    a.    Adult Immunized & Forecast
    b.    Pediatric (Infants) Immunized & Forecast

    3.    Doses of Vaccines Administered (Disease wise) & Forecast (2011 – 2022)

    a.    Doses of vaccines administered in Adults & Forecast 
    b.    Doses of vaccines administered in Pediatric (Infants) & Forecast 

     

    14 Vaccines Studied in the Report are as Follows:

    1. Influenza
    2. Cervical Cancer
    3. Zoster (Shingles)
    4. MMR (Measles, Mumps, and Rubella)
    5. Pneumonia
    6. Meningitis
    7. Hepatitis
    8. Tap (Diphtheria, Tetanus, Pertussis)
    9. Haemophilus influenzae type B
    10. Polio
    11. Rotavirus
    12. Varicella
    13. Combination Vaccine
    14. Travel & Miscellaneous Vaccine

     

    Why This Report a Compulsory Buy!

    • This report offers complete analysis of Disease wise Global Vaccines Market & Forecast (2011 – 2022).
    • This report offers segmented analysis of Disease wise Global Vaccines Market into two segments:
      • Adult Vaccines (Disease wise) Market &Forecast
      • Pediatric (Infant) Vaccines (Disease wise) Market &Forecast
    • This report offers extensive analysis of the number of people Immunized and Number of Vaccines Doses Administered & Forecast (2011 – 2022) by Adult & Pediatric (Infant).
    • This report offers widespread analysis on Vaccine Key Players (Worldwide) & Forecast (2011 – 2022)

     

     

    Press Release: Evolution of New Vaccines drives Health condition globally

     

    Dating back to fifty years, Innovations in technologies have changed health conditions in both developed and developing nations. Likewise, essential childhood immunization at high levels has almost abolished many diseases that once crippled or killed thousands of young children each year. The same vaccines which are originally manufactured in the US and Europe were consequently purchased and used in the developing nations at low prices after manufacturing capacity had been developed. By the year 2022, Renub research anticipates that, Global Vaccines Market to make US$ 60 Billion.


    Vaccines are a very valuable way to deal with poverty

    Immunization is one of the most cost-effective and safest ways to diminish disease and prevent death. It is cheap and safe, and requires comparatively little contact between the health and the patient and preventing illness and death. Global health, Immunization has been one of the great successes. According to the report, in 1974, approximately five percent of the worldwide children had access to vaccines.

    Aftermath from the triumphant effort to eradicate smallpox, a worldwide effort was launched in the year 1980 to get six vaccines for serious childhood diseases to the worldwide children. Due to this effort, and the investments by donors and developing nation governments, millions of all children are now immunized, saving approximately 3 million lives a year.


    New vaccines take too long to reach Developing Nations

    Dating back to years, novel vaccines have been introduced in the developing nations through the regular adoption of vaccines from the developed one. This has been true of almost all of today’s basic immunizations, including polio, diphtheria, tetanus, pertussis, and measles. These products, which were mainly developed for developed countries, have made a massive impact on the developing countries. 

    Nonetheless, after a novel vaccine has been introduced in developed countries, there has been a significant lag before they are cheaply and widely available in developing countries. Because of these lags, millions of children have died from diseases against which they could have been diagnosed.


    Distinguishing Vaccines, Market Shares among Adults & Pediatrics 

    Influenza vaccine leads the adult vaccine market in the year 2017, out of 9 adult vaccines i.e. Influenza, Cervical Cancer, Zoster, MMRV, Pneumococcal, Meningococcal, Hepatitis, TdaP, Travel etc. whereas Combination and Pneumococcal vaccine together accounts for almost 50% of the pediatric vaccine market share. Some of the other Pediatric vaccines market covered in the report were MMR, Influenza, Pneumococcal, Meningococcal, Hepatitis, DTap, Haemophilus Influenzae Type b(Hib) , Polio, Rotavirus, Varicella, Combos.


    Single shot of Combos Vaccines preferred instead of Specific Vaccine 

    Combos (Combination Vaccines) has the most extreme immunization share among every pediatric vaccines (Influenza, MMR, Pneumococcal, Meningococcal, Hepatitis, DTap, Haemophilus Influenzae Type b(Hib), Polio, Rotavirus, Varicella) in the year 2017, contemplated in the report as they secure against more afflictions in single shot, as individuals wanting to go for combination vaccines rather than a precise vaccine.

     
    Administration of Vaccine Doses

    Our analysis found that there is a consistent surge in the number of Pneumococcal and Meningococcal vaccine doses administered in future due to the rising concern about the life-threatening vaccine-preventable diseases around the world.
     

    1.    Research Findings

    2.    Global – Vaccines Market and Forecast
    2.1    Adult Vaccines Market and Forecast

    2.2    Pediatric (Infant) Vaccines Market and Forecast

     

    3.    Global – Adult Vaccine vs. Pediatric Vaccine Market Share

     

    4.    Global – Vaccines Market Share and Forecast
    4.1    Adult Vaccines Market Share and Forecast

    4.2    Pediatric (Infant) Vaccines Market Share and Forecast

     

    5.    Global – People Immunized and Forecast
    5.1    Adult Immunized and Forecast

    5.2    Pediatric (Infant) Immunized and Forecast

     

    6.    Global – People Immunized Share and Forecast
    6.1    Adult Immunized Share and Forecast

    6.2    Pediatric (Infant) Immunized Share and Forecast

     

    7.    Global – Doses of Vaccines Administered and Forecast
    7.1    Doses of Adult Vaccines Administered and Forecast

    7.2    Doses of Pediatric (Infant) Vaccines Administered and Forecast

     

    8.    Global – Doses of Vaccines Administered Share and Forecast
    8.1    Doses of Vaccines Administered to Adult Share and Forecast

    8.2    Doses of Vaccines Administered to Pediatric (Infant) Share and Forecast

     

    9.    Global – Vaccine Companies Market Share and Forecast

     

    10.    Disease wise – Vaccines Market and Forecast
    10.1    Influenza – Total Vaccines Market and Forecast
    10.1.1    Influenza – Adult Vaccines Market and Forecast
    10.1.2    Influenza – Pediatric (Infant) Vaccines Market and Forecast

    10.2    Cervical Cancer (HPV) – Vaccines Market and Forecast

    10.3    Zoster (Shingles) – Vaccines Market and Forecast

    10.4    MMRV and MMR (Measles, Mumps, Rubella, and Varicella Vaccine) – Total Vaccines Market and Forecast
    10.4.1    MMRV – Adult Vaccines Market and Forecast
    10.4.2    MMR – Pediatric (Infant) Vaccines Market and Forecast

    10.5    Pneumococcal – Total Vaccines Market and Forecast
    10.5.1    Pneumococcal – Adult Vaccines Market and Forecast
    10.5.2    Pneumococcal – Pediatric (Infant) Vaccines Market and Forecast

    10.6    Meningococcal – Total Vaccines Market and Forecast
    10.6.1    Meningococcal – Adult Vaccines Market and Forecast
    10.6.2    Meningococcal – Pediatric (Infant) Vaccines Market and Forecast

    10.7    Hepatitis – Total Vaccines Market and Forecast
    10.7.1    Hepatitis – Adult Vaccines Market and Forecast
    10.7.2    Hepatitis – Pediatric (Infant) Vaccines Market and Forecast

    10.8    TdaP and DTaP – Total Vaccines Market and Forecast
    10.8.1    TdaP – Adult Vaccines Market and Forecast
    10.8.2    DTaP – Pediatric (Infant) Vaccines Market and Forecast

    10.9    Travel and Miscellaneous – Vaccines Market and Forecast

    10.10    Haemophilus Influenzae Type B (HIB) – Vaccines Market and Forecast

    10.11    Combos (Combination) – Vaccines Market and Forecast

    10.12    Polio – Vaccines Market and Forecast

    10.13    Rotavirus – Vaccines Market and Forecast

    10.14    Varicella – Vaccines Market and Forecast

     

    11.    Disease wise – People Immunized Numbers and Forecast
    11.1    Influenza – Total Number of People Immunized and Forecast
    11.1.1    Influenza – Number of Adults Immunized and Forecast
    11.1.2    Influenza – Number of Infants Immunized and Forecast

    11.2    Cervical Cancer (HPV) – People Immunized and Forecast

    11.3    Zoster (Shingles) – Number of People Immunized and Forecast

    11.4    MMRV and MMR – Total Number of People Immunized and Forecast
    11.4.1    MMRV – Number of Adults Immunized and Forecast
    11.4.2    MMR – Number of Pediatric (Infants) Immunized and Forecast

    11.5    Pneumococcal – Total Number of People Immunized and Forecast
    11.5.1    Pneumococcal – Number of Adults Immunized and Forecast
    11.5.2    Pneumococcal – Number of Infants Immunized and Forecast

    11.6    Meningococcal – Total Number of People Immunized and Forecast
    11.6.1    Meningococcal – Number of Adults Immunized and Forecast
    11.6.2    Meningococcal – Number of Infants Immunized and Forecast

    11.7    Hepatitis – Total Number of People Immunized and Forecast
    11.7.1    Hepatitis – Number of Adults Immunized and Forecast
    11.7.2    Hepatitis – Number of Infants Immunized and Forecast

    11.8    TdaP and DTaP – Total Number of People Immunized and Forecast
    11.8.1    TdaP – Number of Adults Immunized and Forecast
    11.8.2    DTaP – Number of Infants Immunized and Forecast

    11.9    Hib (Haemophilus Influenzae Type B) – Number of Infants Immunized and Forecast

    11.10    Combos (Combination Vaccines) – Number of Infants Immunized and Forecast

    11.11    Polio – Number of Infants Immunized and Forecast

    11.12    Rotavirus – Number of Infants Immunized and Forecast

    11.13    Varicella – Number of Infants Immunized and Forecast

     

    12.    Disease wise – Doses of Vaccines Administered and Forecast
    12.1    Influenza – Doses of Vaccines Administered and Forecast
    12.1.1    Influenza – Doses of Adult Vaccines Administered and Forecast
    12.1.2    Influenza – Doses of Infant Vaccines Administered and Forecast

    12.2    Cervical Cancer (HPV) – Doses of Vaccines Administered and Forecast

    12.3    Zoster (Shingles) – Doses of Vaccines Administered and Forecast

    12.4    MMRV and MMR – Doses of Vaccines Administered and Forecast
    12.4.1    MMRV – Doses of Adult Vaccines Administered and Forecast
    12.4.2    MMR – Doses of Infant Vaccines Administered and Forecast

    12.5    Pneumococcal – Doses of Vaccines Administered and Forecast
    12.5.1    Pneumococcal – Doses of Adult Vaccines Administered and Forecast
    12.5.2    Pneumococcal – Doses of Infant Vaccines Administered and Forecast

    12.6    Meningococcal – Doses of Vaccines Administered and Forecast
    12.6.1    Meningococcal – Doses of Adult Vaccines Administered and Forecast
    12.6.2    Meningococcal – Doses of Infant Vaccines Administered and Forecast

    12.7    Hepatitis – Doses of Vaccines Administered and Forecast
    12.7.1    Hepatitis – Doses of Adult Vaccines Administered and Forecast
    12.7.2    Hepatitis – Doses of Infant Vaccines Administered and Forecast

    12.8    TdaP and DTaP – Doses of Vaccines Administered and Forecast
    12.8.1    TdaP – Doses of Adult Vaccines Administered and Forecast
    12.8.2    DTaP – Doses of Infant Vaccines Administered and Forecast

    12.9    Hib (Haemophilus Influenzae Type B) – Doses of Infant Vaccines Administered and Forecast

    12.10    Polio – Doses of Infant Vaccines Administered and Forecast

    12.11    Rotavirus – Doses of Infant Vaccines Administered and Forecast

    12.12    Varicella – Doses of Infant Vaccines Administered and Forecast

     

    13.    Disease wise - Immunization Profile
    13.1    Immunization Coverage (%) in Infants (2005 – 2015)

    13.2    Global Immunization Profile (2011 – 2015)

    13.3    Regional Immunization Profile (2001 – 2015)
    13.3.1    Measles – Number of Cases Reported
    13.3.2    Mumps – Number of Cases Reported
    13.3.3    Rubella – Number of Cases Reported
    13.3.4    Rubella (CRS) – Number of Cases Reported
    13.3.5    Diphtheria – Number of Cases Reported
    13.3.6    Tetanus (Neonatal) – Number of Cases Reported
    13.3.7    Tetanus (Total) – Number of Cases Reported
    13.3.8    Pertussis – Number of Cases Reported
    13.3.9    Polio – Number of Cases Reported
    13.3.10    Yellow Fever – Number of Cases Reported
    13.3.11    Japanese encephalitis – Number of Cases Reported, 2006 - 2015

     

    14.    Vaccines Key Players Sales and Forecast
    14.1    GlaxoSmithKline, plc.’s Vaccines Sales and Forecast

    14.2    Merck & Co. Vaccines Sales and Forecast

    14.3    Sanofi Pasteur’s Vaccines Sales and Forecast

    14.4    Worldwide - Pfizer, Inc.’s Vaccines Sales and Forecast

    14.5    Worldwide - Others Vaccines Sales and Forecast

     

    15.    Vaccines – Products and Pipeline
    15.1    GSK Vaccine Product Pipeline

    15.2    Merck Vaccine Product Pipeline

    15.3    Sanofi Vaccine Product Pipeline

    15.4    Pfizer Vaccine Product Pipeline

     

    16.    Top Mergers and Acquisitions in the Vaccine Industry

     

    17.    Vaccines and Regulator’s Interventions
    17.1    Making and Meeting Standards of Quality and Safety

    17.2    Vaccine Funding

     

    18.    Vaccine Market Drivers
    18.1    Inclusion in National Immunization Schedule

    18.2    Growing Immunization Coverage for HPV Vaccines

    18.3    Increase in Prevalence of Infectious Diseases

    18.4    Global Immunization Vision and Strategy (GIVS)

    18.5    GAVI Model Fuelling Vaccine Manufacturers
    18.5.1    The Partnership Model
    18.5.2    The Business Model

    18.6    Increasing Vaccine Availability in United States

    18.7    The Vaccine Safety Data link Project

    18.8    The Vaccine Injury Compensation Program

    18.9    Transforming of Vaccine Technologies

    18.10    Global Vaccine Action Plan by WHO (2011 - 2020)

    18.11    Continuous Focus on Effective Communication Strategies

     

    19.    Vaccines Market Challenges
    19.1    Hurdles to Optimal use of Licensed Vaccines
    19.1.1    Technical Obstacles
    19.1.2    Economic Obstacles
    19.1.3    Cultural Obstacles

    19.2    Complexity of Vaccine Development & Approval System Thwarts Product Development
    19.2.1    Legal Obstacles
    19.2.2    General Technical Barriers
    19.2.3    Economic Barriers
    19.2.4    Regulatory Barriers

    19.3    Shortening the Timeline for Vaccine Development

    19.4    Refusal/Resistance to Vaccination
    19.4.1    Vaccine Adverse Event Reporting System

    19.5    Vaccine Shortages and Delays

    19.6    Obstacles in Vaccine Research & Development

    19.7    Barriers to New Entrants in the Vaccines Market
     

    List of Figures


    Figure 2‑1: Global – Vaccines Market (Billion US$), 2011 - 2016
    Figure 2‑2: Global – Forecast for Vaccines Market (Billion US$), 2017 – 2022
    Figure 2‑3: Global – Adult Vaccines Market (Billion US$), 2011 – 2016
    Figure 2‑4: Global – Forecast for Adult Vaccines Market (Billion US$), 2017 – 2022
    Figure 2‑5: Global – Pediatric (Infant) Vaccines Market (Billion US$), 2011 – 2016
    Figure 2‑6: Global – Forecast for Pediatric (Infant) Vaccines Market (Billion US$), 2017 – 2022

    Figure 3‑1: Global – Adult Vs. Pediatric Vaccine Market Share
    Figure 3‑2: Global – Forecast for Adult Vs. Pediatric Vaccine Market Share

    Figure 5‑1: Global – People Immunized (Million), 2011 - 2016
    Figure 5‑2: Global – People Immunized (Million), 2017 - 2022
    Figure 5‑3: Global – Adult Immunized (Million), 2011 – 2016
    Figure 5‑4: Global – Forecast for Adult Immunized (Million), 2017 – 2022
    Figure 5‑5: Global – Pediatric (Infant) Immunized (Million), 2011 - 2016
    Figure 5‑6: Global – Forecast for Pediatric (Infant) Immunized (Million), 2017 – 2022

    Figure 7‑1: Global – Doses of Vaccines Administered (Million), 2011 - 2016
    Figure 7‑2: Global – Forecast for Doses of Vaccines Administered (Million), 2017 – 2022
    Figure 7‑3: Global – Doses of Adult Vaccines Administered (Million), 2011 - 2016
    Figure 7‑4: Global – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022
    Figure 7‑5: Global – Doses of Pediatric (Infant) Vaccines Administered (Million), 2011 - 2016
    Figure 7‑6: Global – Forecast for Doses of Pediatric (Infant) Vaccines Administered (Million), 2017 - 2022

    Figure 9‑1: Global – Key Players Vaccines Market Share (Percent), 2011 - 2016
    Figure 9‑2: Global – Forecast for Key Players Vaccines Market Share (Percent), 2017 - 2022

    Figure 10‑1: Influenza – Total Vaccines Market (Billion US$), 2011 - 2016
    Figure 10‑2: Influenza – Forecast for Total Vaccines Market (Billion US$), 2017 - 2022
    Figure 10‑3: Influenza – Adult Vaccines Market (Billion US$), 2011 - 2016
    Figure 10‑4: Influenza – Forecast for Adult Vaccines Market (Billion US$), 2017 – 2022
    Figure 10‑5: Influenza – Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2016
    Figure 10‑6: Influenza – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2017 - 2022
    Figure 10‑7: Cervical Cancer (HPV) – Vaccines Market (Billion US$), 2011 – 2016
    Figure 10‑8: Cervical Cancer (HPV) – Forecast for Vaccines Market (Billion US$), 2017 - 2022
    Figure 10‑9: Zoster (Shingles) – Vaccines Market (Billion US$), 2011 - 2016
    Figure 10‑10: Zoster (Shingles) – Forecast for Vaccines Market (Billion US$), 2017 - 2022
    Figure 10‑11: MMRV and MMR – Total Vaccines Market (Billion US$), 2011 - 2016
    Figure 10‑12: MMRV and MMR – Forecast for Total Vaccines Market (Billion US$), 2017 – 2022
    Figure 10‑13: MMRV – Adult Vaccines Market (Million US$), 2011 – 2016
    Figure 10‑14: MMRV – Forecast for Adult Vaccines Market (Million US$), 2017 – 2022
    Figure 10‑15: MMR – Pediatric (Infant) Vaccines Market (Million US$), 2011 – 2016
    Figure 10‑16: MMR – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2017 - 2022
    Figure 10‑17: Pneumococcal – Total Vaccines Market (Billion US$), 2011 - 2016
    Figure 10‑18: Pneumococcal – Forecast for Total Vaccines Market (Billion US$), 2017 - 2022
    Figure 10‑19: Pneumococcal – Adult Vaccines Market (Billion US$), 2011 - 2016
    Figure 10‑20: Pneumococcal – Forecast for Adult Vaccines Market (Billion US$), 2017 – 2022
    Figure 10‑21: Pneumococcal – Pediatric (Infant) Vaccines Market (Billion US$), 2011 - 2016
    Figure 10‑22: Pneumococcal – Forecast for Pediatric (Infant) Vaccines Market (Billion US$), 2017 - 2022
    Figure 10‑23: Areas with frequent epidemics of meningococcal meningitis
    Figure 10‑24: Meningococcal – Total Vaccines Market (Billion US$), 2011 – 2016
    Figure 10‑25: Meningococcal – Forecast for Total Vaccines Market (Billion US$), 2017 – 2022
    Figure 10‑26: Meningococcal – Adult Vaccines Market (Million US$), 2011 – 2016
    Figure 10‑27: Meningococcal – Forecast for Adult Vaccines Market (Million US$), 2017 - 2022
    Figure 10‑28: Meningococcal – Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2016
    Figure 10‑29: Meningococcal – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2017 - 2022
    Figure 10‑30: Hepatitis – Total Vaccines Market (Billion US$), 2011 - 2016
    Figure 10‑31: Hepatitis – Forecast for Total Vaccines Market (Billion US$), 2017 - 2022
    Figure 10‑32: Hepatitis – Adult Vaccines Market (Billion US$), 2011 - 2016
    Figure 10‑33: Hepatitis – Forecast for Adult Vaccines Market (Billion US$), 2017 - 2022
    Figure 10‑34: Hepatitis – Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2016
    Figure 10‑35: Hepatitis – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2017 - 2022
    Figure 10‑36: TdaP and DTaP – Total Vaccines Market (Billion US$), 2011 - 2016
    Figure 10‑37: TdaP and DTaP – Forecast for Total Vaccines Market (Billion US$), 2017 - 2022
    Figure 10‑38: TdaP – Adult Vaccines Market (Million US$), 2011 - 2016
    Figure 10‑39: TdaP – Forecast for Adult Vaccines Market (Million US$), 2017 - 2022
    Figure 10‑40: DTaP – Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2016
    Figure 10‑41: DTaP – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2017 - 2022
    Figure 10‑42: Travel and Miscellaneous – Vaccines Market (Billion US$), 2011 - 2016
    Figure 10‑43: Travel and Miscellaneous – Forecast for Vaccines Market (Billion US$), 2017 - 2022
    Figure 10‑44: Haemophilus Influenzae Type B (HIB) – Vaccines Market (Million US$), 2011 - 2016
    Figure 10‑45: Haemophilus Influenzae Type B (HIB) – Forecast for Vaccines Market (Million US$), 2017 - 2022
    Figure 10‑46: Combos (Combination) – Vaccines Market (Billion US$), 2011 - 2016
    Figure 10‑47: Combos (Combination) – Forecast for Vaccines Market (Billion US$), 2017 - 2022
    Figure 10‑48: Polio – Vaccines Market (Million US$), 2011 - 2016
    Figure 10‑49: Polio – Forecast for Vaccines Market (Million US$), 2017 - 2022
    Figure 10‑50: Rotavirus Deaths Under Five Years of Age per 100 000 Population <5 Years of Age, 2013
    Figure 10‑51: Ten Countries Accounting for Almost Two Thirds of All Deaths, 2013
    Figure 10‑52: Rotavirus – Vaccines Market (Million US$), 2011 - 2016
    Figure 10‑53: Rotavirus – Forecast for Vaccines Market (Million US$), 2017 - 2022
    Figure 10‑54: Varicella – Vaccines Market (Billion US$), 2011 - 2016
    Figure 10‑55: Varicella – Forecast for Vaccines Market (Billion US$), 2017 – 2022

    Figure 11‑1: Influenza – Total Number of People Immunized (Million), 2011 - 2016
    Figure 11‑2: Influenza – Forecast for Total Number of People Immunized (Million), 2017 – 2022
    Figure 11‑3: Influenza – Number of Adults Immunized (Thousand), 2011 - 2016
    Figure 11‑4: Influenza – Forecast for Number of Adults Immunized (Thousand), 2017 - 2022
    Figure 11‑5: Influenza – Number of Infants Immunized (Thousand), 2011 - 2016
    Figure 11‑6: Influenza – Forecast for Number of Infants Immunized (Thousand), 2017 - 2022
    Figure 11‑7: Cervical Cancer – Number of People Immunized (Thousand), 2011 - 2016
    Figure 11‑8: Cervical Cancer – Forecast for Number of People Immunized (Thousand), 2017 - 2022
    Figure 11‑9: Zoster (Shingles) – Number of People Immunized (Thousand), 2011 - 2016
    Figure 11‑10: Zoster (Shingles) – Forecast for Number of People Immunized (Thousand), 2017 - 2022
    Figure 11‑11: MMRV and MMR – Total Number of People Immunized (Million), 2011 - 2016
    Figure 11‑12: MMRV and MMR – Forecast for Total Number of People Immunized (Million), 2017 - 2022
    Figure 11‑13: MMRV – Number of Adults Immunized (Thousand), 2011 - 2016
    Figure 11‑14: MMRV – Forecast for Number of Adults Immunized (Thousand), 2017 - 2022
    Figure 11‑15: MMR – Number of Pediatric (Infants) Immunized (Thousand), 2011 - 2016
    Figure 11‑16: MMR – Forecast for Number of Pediatric (Infants) Immunized (Thousand), 2017 - 2022
    Figure 11‑17: Pneumococcal – Total Number of People Immunized (Million), 2011 - 2016
    Figure 11‑18: Pneumococcal – Forecast for Total Number of People Immunized (Million), 2017 - 2022
    Figure 11‑19: Pneumococcal – Number of Adults Immunized (Thousand), 2011 - 2016
    Figure 11‑20: Pneumococcal – Forecast for Number of Adults Immunized (Thousand), 2017 - 2022
    Figure 11‑21: Pneumococcal – Number of Infants Immunized (Thousand), 2011 - 2016
    Figure 11‑22: Pneumococcal – Forecast for Number of Infants Immunized (Thousand), 2011 - 2016
    Figure 11‑23: Meningococcal – Total Number of People Immunized (Million), 2011 – 2016
    Figure 11‑24: Meningococcal – Forecast for Total Number of People Immunized (Million), 2017 - 2022
    Figure 11‑25: Meningococcal – Number of Adults Immunized (Thousand), 2011 - 2016
    Figure 11‑26: Meningococcal – Forecast for Number of Adults Immunized (Thousand), 2017 - 2022
    Figure 11‑27: Meningococcal – Number of Infants Immunized (Thousand), 2011 - 2016
    Figure 11‑28: Meningococcal – Forecast for Number of Infants Immunized (Thousand), 2017 - 2022
    Figure 11‑29: Hepatitis – Total Number of People Immunized (Million), 2011 - 2016
    Figure 11‑30: Hepatitis – Forecast for Total Number of People Immunized (Million), 2017 - 2022
    Figure 11‑31: Hepatitis – Number of Adults Immunized (Thousand), 2011 - 2016
    Figure 11‑32: Hepatitis – Forecast for Number of Adults Immunized (Thousand), 2017 - 2022
    Figure 11‑33: Hepatitis – Number of Infants Immunized (Thousand), 2011 - 2016
    Figure 11‑34: Hepatitis – Forecast for Number of Infants Immunized (Thousand), 2017 - 2022
    Figure 11‑35: TdaP and DTaP – Total Number of People Immunized (Million), 2011 - 2016
    Figure 11‑36: TdaP and DTaP – Forecast for Total Number of People Immunized (Million), 2017 - 2022
    Figure 11‑37: TdaP – Number of Adults Immunized (Thousand), 2011 - 2016
    Figure 11‑38: TdaP – Number of Adults Immunized (Thousand), 2017 - 2022
    Figure 11‑39: DTaP – Number of Infants Immunized (Thousand), 2011 - 2016
    Figure 11‑40: DTaP – Forecast for Number of Infants Immunized (Thousand), 2017 - 2022
    Figure 11‑41: Hib (Haemophilus Influenzae Type B) – Number of Infants Immunized (Million), 2011 - 2016
    Figure 11‑42: Hib (Haemophilus Influenzae Type B) – Forecast for Number of Infants Immunized (Million), 2017 - 2022
    Figure 11‑43: Combos (Combination Vaccines) – Number of Infants Immunized (Million), 2011 - 2016
    Figure 11‑44: Combos (Combination Vaccines) – Forecast for Number of Infants Immunized (Million), 2017 - 2022
    Figure 11‑45: Polio – Number of Infants Immunized (Million), 2011 - 2016
    Figure 11‑46: Polio – Forecast for Number of Infants Immunized (Million), 2017 - 2022
    Figure 11‑47: Rotavirus – Number of Infants Immunized (Million), 2011 - 2016
    Figure 11‑48: Rotavirus – Forecast for Number of Infants Immunized (Million), 2017 - 2022
    Figure 11‑49: Varicella – Number of Infants Immunized (Million), 2011 - 2016
    Figure 11‑50: Varicella – Forecast for Number of Infants Immunized (Million), 2017 - 2022

    Figure 12‑1: Influenza – Doses of Vaccines Administered (Million), 2011 - 2016
    Figure 12‑2: Influenza – Forecast for Doses of Vaccines Administered (Million), 2017 - 2022
    Figure 12‑3: Influenza – Doses of Adult Vaccines Administered (Million), 2011 - 2016
    Figure 12‑4: Influenza – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022
    Figure 12‑5: Influenza – Doses of Infant Vaccines Administered (Million), 2011 - 2016
    Figure 12‑6: Influenza – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
    Figure 12‑7: Cervical Cancer (HPV) – Doses of Vaccines Administered (Million), 2011 - 2016
    Figure 12‑8: Cervical Cancer (HPV) – Forecast for Doses of Vaccines Administered (Million), 2017 - 2022
    Figure 12‑9: Zoster (Shingles) – Doses of Vaccines Administered (Million), 2011 - 2016
    Figure 12‑10: Zoster (Shingles) – Forecast for Doses of Vaccines Administered (Million), 2017 - 2022
    Figure 12‑11: MMRV and MMR – Doses of Vaccines Administered (Million), 2011 - 2016
    Figure 12‑12: MMRV and MMR – Forecast for Doses of Vaccines Administered (Million), 2017 - 2022
    Figure 12‑13: MMRV – Doses of Adult Vaccines Administered (Million), 2011 - 2016
    Figure 12‑14: MMRV – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022
    Figure 12‑15: MMR – Doses of Infant Vaccines Administered (Million), 2011 - 2016
    Figure 12‑16: MMR – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
    Figure 12‑17: Pneumococcal – Doses of Vaccines Administered (Million), 2011 - 2016
    Figure 12‑18: Pneumococcal – Forecast for Doses of Vaccines Administered (Million), 2017 - 2022
    Figure 12‑19: Pneumococcal – Doses of Adult Vaccines Administered (Million), 2011 - 2016
    Figure 12‑20: Pneumococcal – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022
    Figure 12‑21: Pneumococcal – Doses of Infant Vaccines Administered (Million), 2011 - 2016
    Figure 12‑22: Pneumococcal – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
    Figure 12‑23: Meningococcal – Doses of Vaccines Administered (Million), 2011 - 2016
    Figure 12‑24: Meningococcal – Forecast for Doses of Vaccines Administered (Million), 2017 - 2022
    Figure 12‑25: Meningococcal – Doses of Adult Vaccines Administered (Million), 2011 - 2016
    Figure 12‑26: Meningococcal – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022
    Figure 12‑27: Meningococcal – Doses of Infant Vaccines Administered (Million), 2011 - 2016
    Figure 12‑28: Meningococcal – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
    Figure 12‑29: Hepatitis – Doses of Vaccines Administered (Million), 2011 - 2016
    Figure 12‑30: Hepatitis – Forecast for Doses of Vaccines Administered (Million), 2017 - 2022
    Figure 12‑31: Hepatitis – Doses of Adult Vaccines Administered (Million), 2011 - 2016
    Figure 12‑32: Hepatitis – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022
    Figure 12‑33: Hepatitis – Doses of Infant Vaccines Administered (Million), 2011 - 2016
    Figure 12‑34: Hepatitis – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
    Figure 12‑35: TdaP and DTaP – Doses of Vaccines Administered (Million), 2011 - 2016
    Figure 12‑36: TdaP and DTaP – Forecast for Doses of Vaccines Administered (million), 2017 - 2022
    Figure 12‑37: TdaP – Doses of Adult Vaccines Administered (Million), 2011 - 2016
    Figure 12‑38: TdaP – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022
    Figure 12‑39: DTaP – Doses of Infant Vaccines Administered (Million), 2011 - 2016
    Figure 12‑40: DTaP – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
    Figure 12‑41: Hib (Haemophilus Influenzae Type B) – Doses of Infant Vaccines Administered (Million), 2011 - 2016
    Figure 12‑42: Hib (Haemophilus Influenzae Type B) – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
    Figure 12‑43: Polio – Doses of Infant Vaccines Administered (Million), 2011 - 2016
    Figure 12‑44: Polio – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
    Figure 12‑45: Rotavirus – Doses of Infant Vaccines Administered (Million), 2011 - 2016
    Figure 12‑46: Rotavirus – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
    Figure 12‑47: Varicella – Doses of Infant Vaccines Administered (Million), 2011 - 2016
    Figure 12‑48: Varicella – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022

    Figure 13‑1: Worldwide Immunization Coverage (%) in Infants, 2005- 2010
    Figure 13‑2: Worldwide Immunization Coverage (%) in Infants, 2011- 2015

    Figure 14‑1: Worldwide - GlaxoSmithKline, plc.’s Vaccines Sales (Billion US$), 2011 - 2016
    Figure 14‑2: Worldwide – Forecast for GlaxoSmithKline, plc.’s Vaccines Sales (Billion US$), 2017 - 2022
    Figure 14‑3: Worldwide - Merck & Co. Vaccines Sales (Billion US$), 2011 - 2016
    Figure 14‑4: Worldwide – Forecast for Merck & Co. Vaccines Sales (Billion US$), 2017 - 2022
    Figure 14‑5: Worldwide - Sanofi Pasteur’s Vaccines Sales (Billion US$), 2011 - 2022
    Figure 14‑6: Worldwide – Forecast for Sanofi Pasteur’s Vaccines Sales (Billion US$), 2017 - 2022
    Figure 14‑7: Worldwide - Pfizer, Inc.’s Vaccines Sales (Billion US$), 2011 - 2016
    Figure 14‑8: Worldwide – Forecast for Pfizer, Inc.’s Vaccines Sales (Billion US$), 2017 - 2022
    Figure 14‑9: Worldwide - Others Vaccines Sales (Billion US$), 2011 - 2016
    Figure 14‑10: Worldwide – Forecast for Others Vaccines Sales (Billion US$), 2017 - 2022

    Figure 15‑1: GSK Vaccine Product Pipeline

    Figure 18‑1: Countries with HPV Vaccination Program listed on their National Immunization Program (NIP) Schedule
    Figure 18‑2: Number of Cases of Diphtheria, Pertussis, Tetnaus & Measles by Major Region Worldwide, 2013
    Figure 18‑3: Vaccines Procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
    Figure 18‑4: Vaccines procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
    Figure 18‑5: US Retail Clinics Expected to Surge by 2017

     

    Lists of Tables

    Table 2‑1: Vaccine Recommendations
    Table 2‑2: Other Recommended Vaccines

    Table 4‑1: Global – Vaccines Market Share (Percent), 2011 - 2016
    Table 4‑2: Global – Forecast for Vaccines Market Share (Percent), 2017 - 2022
    Table 4‑3: Global – Adult Vaccines Market Share (Percent), 2011 - 2016
    Table 4‑4: Global – Adult Vaccines Market Share (Percent), 2017 - 2022
    Table 4‑5: Global – Pediatric (Infant) Vaccines Market Share (Percent), 2011 - 2016
    Table 4‑6: Global – Forecast for Pediatric (Infant) Vaccines Market Share (Percent), 2017 - 2022

    Table 6‑1: Global – People Immunized Share (Percent), 2011 - 2016
    Table 6‑2: Global – Forecast for People Immunized Share (Percent), 2017 – 2022
    Table 6‑3: Global – Adult Immunized Share (Percent), 2011 - 2016
    Table 6‑4: Global – Forecast for Adult Immunized Share (Percent), 2017 – 2022
    Table 6‑5: Global – Pediatric (Infant) Immunized Share (Percent), 2011 – 2016
    Table 6‑6: Global – Forecast for Pediatric (Infant) Immunized Share (Percent), 2017 – 2022

    Table 8‑1: Global – Doses of Vaccines Administered Share (Percent), 2011 - 2016
    Table 8‑2: Global – Forecast for Doses of Vaccines Administered Share (Percent), 2017 - 2022
    Table 8‑3: Global – Doses of Vaccines Administered to Adult Share (Percent), 2011 - 2016
    Table 8‑4: Global – Forecast for Doses of Vaccines Administered to Adult Share (Percent), 2017 - 2022
    Table 8‑5: Global – Doses of Vaccines Administered to Pediatric (Infant) Share (Percent), 2011 - 2016
    Table 8‑6: Global – Forecast for Doses of Vaccines Administered to Pediatric (Infant) Share (Percent), 2017 - 2022

    Table 13‑1: Vaccines – Number of Reported Cases, 2011 – 2015
    Table 13‑2: Measles – Number of Cases Reported, 2001 – 2015
    Table 13‑3: Mumps – Number of Cases Reported, 2001 - 2015
    Table 13‑4: Rubella – Number of Cases Reported, 2001 - 2015
    Table 13‑5: Rubella (CRS) – Number of Cases Reported, 2001 - 2015
    Table 13‑6: Diphtheria – Number of Cases Reported, 2001 - 2015
    Table 13‑7: Tetanus (Neonatal) – Number of Cases Reported, 2001 – 2015
    Table 13‑8: Tetanus (Total) – Number of Cases Reported, 2001 - 2015
    Table 13‑9: Pertussis – Number of Cases Reported, 2001 - 2015
    Table 13‑10: Polio – Number of Cases Reported, 2001 - 2015
    Table 13‑11: Yellow Fever – Number of Cases Reported, 2001 - 2015
    Table 13‑12: Japanese Encephalitis – Number of Cases Reported, 2006 - 2015

    Table 15‑1: Merck Vaccine Product Pipeline
    Table 15‑2: Sanofi Vaccine Product Pipeline
    Table 15‑3: Pfizer Vaccine Product Pipeline

    Table 16‑1: Vaccine Mergers & Acquisitions

    Table 18‑1: United States Immunization Schedule
    Table 18‑2: Afghanistan Immunization Schedule
    Table 18‑3: Norway Immunization Schedule
    Table 18‑4: India Immunization Schedule
    Table 18‑5: Vietnam Immunization Schedule
    Table 18‑6: Worldwide – Total Future Deaths Averted through Vaccination (Million), 2011 – 2020
    Table 18‑7: Goal-Level Indicators, 2015 & 2020
    Table 18‑8: Improvement Strategies or Requirements – the Joint Commission and the Project’s Collaborating Organizations


    Related Products